*2015, ViiV Healthcare partnered with the University of North Carolina at Chapel Hill to establish Qura Therapeutics, which focuses on developing an HIV cure.
*Qura Therapeutics supports the UNC HIV Cure Center with financial and material resources. The partnership also helps develop therapies that result from the research.
"One of Qura Therapeutics' research strategies is "Induce and Reduce", which aims to make hidden HIV visible to the immune system and help the patient's immune system fight the virus."
*UNC Global Health Director, Institute for Global Health and Infectious Diseases:
Dr. Myron Cohen.
*https://www.med.unc.edu/medicine/infdis/people/myron-cohen-md/
Fall back to Oct. 2016 with Dr. J:
"Dr. Myron Cohen is chief of infectious diseases at the University of North Carolina School of Medicine at Chapel Hill
https://apnews.com/article/health-united-stat...12654019dc
____
Qura owned by ViiV.
Exposing hidden HIV, is right in-line with adding to our FcRn knowledge base of collaborators.
___
On a side note, below Dr. Lataillade simply adds more confidence GSK / Pfizer / ViiV, would be an outstanding postitioning of Leronlimab.
Removing any shareholder worries that a BP would shelve LL.
Going to add, below comment will/would, also carry forward into all of the LL indications he targets outside HIV.
___
“We always say to patients, why do you need to take more drugs when you don't have to?” Lataillade said.
As a practicing physician, Lataillade says the “hot topics” he hears about in the clinic are even more long-lasting treatments and improving patients' immune systems so they work just like anyone else's.
Patients want to stretch out their treatments as long as possible and have self-administered options, as well.
https://www.fiercebiotech.com/biotech/fierce-...t-cure-hiv
___
Que the safe, CCRS axis Monoclonal antibodies:
Leronlimab
&
Leronlimab-PLS
___
Max has a monumental humanitarian task @ hand.
History will be thanking him for generations to come.
"Will update soon"
Dr. Max Lataillade
*Qura Therapeutics supports the UNC HIV Cure Center with financial and material resources. The partnership also helps develop therapies that result from the research.
"One of Qura Therapeutics' research strategies is "Induce and Reduce", which aims to make hidden HIV visible to the immune system and help the patient's immune system fight the virus."
*UNC Global Health Director, Institute for Global Health and Infectious Diseases:
Dr. Myron Cohen.
*https://www.med.unc.edu/medicine/infdis/people/myron-cohen-md/
Fall back to Oct. 2016 with Dr. J:
"Dr. Myron Cohen is chief of infectious diseases at the University of North Carolina School of Medicine at Chapel Hill
https://apnews.com/article/health-united-stat...12654019dc
____
Qura owned by ViiV.
Exposing hidden HIV, is right in-line with adding to our FcRn knowledge base of collaborators.
___
On a side note, below Dr. Lataillade simply adds more confidence GSK / Pfizer / ViiV, would be an outstanding postitioning of Leronlimab.
Removing any shareholder worries that a BP would shelve LL.
Going to add, below comment will/would, also carry forward into all of the LL indications he targets outside HIV.
___
“We always say to patients, why do you need to take more drugs when you don't have to?” Lataillade said.
As a practicing physician, Lataillade says the “hot topics” he hears about in the clinic are even more long-lasting treatments and improving patients' immune systems so they work just like anyone else's.
Patients want to stretch out their treatments as long as possible and have self-administered options, as well.
https://www.fiercebiotech.com/biotech/fierce-...t-cure-hiv
___
Que the safe, CCRS axis Monoclonal antibodies:
Leronlimab
&
Leronlimab-PLS
___
Max has a monumental humanitarian task @ hand.
History will be thanking him for generations to come.
"Will update soon"
Dr. Max Lataillade
1